WEBSITE BSE:543828 NSE : SUDARSHAN 17 May, 10:07
Market Cap ₹163 Cr.
Stock P/E 0.0
P/B 1.6
Current Price ₹67.8
Book Value ₹ 42
Face Value 10
52W High ₹91.9
Dividend Yield 0.44%
52W Low ₹ 62
Sudarshan Pharma Industries Ltd is a prominent pharmaceutical company renowned for its high-quality and innovative healthcare solutions. With a steadfast commitment to advancing medical care, the company specializes in the research, development, and manufacturing of a diverse range of pharmaceutical products. Its comprehensive portfolio encompasses prescription medications, over-the-counter drugs, and healthcare essentials. Sudarshan Pharma Industries Ltd is dedicated to upholding rigorous quality standards, ensuring the safety and efficacy of its offerings. With a focus on sustainable practices, cutting-edge research, and a customer-centric approach, the company has garnered a strong reputation within the pharmaceutical industry. Through its unwavering dedication to improving global health, Sudarshan Pharma Industries Ltd continues to make significant contributions to the well-being of individuals worldwide.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|
| Net Sales | 193 | 357 | 461 | |
| Other Income | 0 | 0 | 1 | |
| Total Income | 194 | 358 | 462 | |
| Total Expenditure | 186 | 346 | 447 | |
| Operating Profit | 8 | 11 | 16 | |
| Interest | 3 | 3 | 5 | |
| Depreciation | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 4 | 7 | 9 | |
| Provision for Tax | 1 | 2 | 2 | |
| Profit After Tax | 3 | 5 | 7 | |
| Adjustments | 0 | -0 | 0 | |
| Profit After Adjustments | 3 | 5 | 7 | |
| Adjusted Earnings Per Share | 2.8 | 5.4 | 2.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 29% | 0% | 0% | 0% |
| Operating Profit CAGR | 45% | 0% | 0% | 0% |
| PAT CAGR | 40% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -1% | NA% | NA% | NA% |
| ROE Average | 11% | 14% | 14% | 14% |
| ROCE Average | 15% | 16% | 16% | 16% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Shareholder's Funds | 23 | 30 | 101 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 5 | 5 | 13 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Current Liabilities | 71 | 103 | 118 |
| Total Liabilities | 99 | 138 | 232 |
| Fixed Assets | 6 | 6 | 20 |
| Other Non-Current Assets | 5 | 1 | 14 |
| Total Current Assets | 88 | 130 | 199 |
| Total Assets | 99 | 138 | 232 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 0 |
| Cash Flow from Operating Activities | 3 | -4 | -29 |
| Cash Flow from Investing Activities | -1 | -1 | -26 |
| Cash Flow from Financing Activities | -1 | 4 | 66 |
| Net Cash Inflow / Outflow | -0 | -1 | 11 |
| Closing Cash & Cash Equivalent | 1 | 0 | 12 |
| # | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Earnings Per Share (Rs) | 2.8 | 5.38 | 2.92 |
| CEPS(Rs) | 3.58 | 6.27 | 3.3 |
| DPS(Rs) | 0 | 0 | 0.3 |
| Book NAV/Share(Rs) | 23.58 | 30.54 | 41.96 |
| Core EBITDA Margin(%) | 3.71 | 3.06 | 3.18 |
| EBIT Margin(%) | 3.52 | 2.94 | 3.23 |
| Pre Tax Margin(%) | 1.85 | 2 | 2.06 |
| PAT Margin (%) | 1.38 | 1.47 | 1.53 |
| Cash Profit Margin (%) | 1.77 | 1.71 | 1.72 |
| ROA(%) | 2.69 | 4.43 | 3.8 |
| ROE(%) | 11.87 | 20.08 | 10.76 |
| ROCE(%) | 13.01 | 18.67 | 15.25 |
| Receivable days | 114.01 | 68.42 | 61.31 |
| Inventory Days | 45.24 | 36.2 | 48.04 |
| Payable days | 90.88 | 64.25 | 70.15 |
| PER(x) | 0 | 0 | 19.08 |
| Price/Book(x) | 0 | 0 | 1.33 |
| Dividend Yield(%) | 0 | 0 | 0.54 |
| EV/Net Sales(x) | 0.2 | 0.11 | 0.34 |
| EV/Core EBITDA(x) | 5.05 | 3.52 | 9.91 |
| Net Sales Growth(%) | 0 | 84.69 | 29.19 |
| EBIT Growth(%) | 0 | 54.63 | 41.69 |
| PAT Growth(%) | 0 | 96.49 | 34.07 |
| EPS Growth(%) | 0 | 92.34 | -45.68 |
| Debt/Equity(x) | 1.32 | 1.03 | 0.34 |
| Current Ratio(x) | 1.23 | 1.26 | 1.68 |
| Quick Ratio(x) | 0.89 | 0.81 | 1.05 |
| Interest Cover(x) | 2.11 | 3.11 | 2.76 |
| Total Debt/Mcap(x) | 0 | 0 | 0.25 |
| # | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 57.39 | 57.39 | 57.39 |
| FII | 3.58 | 1.4 | 1.4 |
| DII | 0 | 0 | 0 |
| Public | 39.03 | 41.21 | 41.21 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 1.38 | 1.38 | 1.38 |
| FII | 0.09 | 0.03 | 0.03 |
| DII | 0 | 0 | 0 |
| Public | 0.94 | 0.99 | 0.99 |
| Others | 0 | 0 | 0 |
| Total | 2.41 | 2.41 | 2.41 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
